|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Addressing Gender Disparities in Urology and Genitourinary Cancer Research
|
|
Andrea Miyahira, Ph.D.
|
| Gender disparities –the underrepresentation of women and other gender minorities—have historically and continually plagued many fields of medicine and scientific research. The fields of urology, genitourinary (GU) oncology, and prostate cancer research have especially been male-dominated.
|
|
|
|
|
|
|
|
|
|
|
|
|
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer
|
Maha Hussain, MD, FACP, FASCO
Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations.
|
|
|
|
|
|
|
|
|
|
|
| The PCF Women in Science Forum: Empowering Female Researchers Through Networking and Mentorship |
| Veda N. Giri, MD, Ayesha Shafi, Ph.D., BA, and Claire Fletcher, Ph.D. |
| Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum aims to build a strong network of women in prostate cancer research and address gender inequities in science. |
|
|
|
|
|
|
|
|
|
|
|
| APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care |
Silke Gillessen, MD
Silke Gillessen discusses upcoming APCCC 2024 and delves into how the conference will tackle crucial topics from GU ASCO 2024, highlighting the dynamic field of prostate cancer treatment. |
|
|
|
|
|
|
|
|
|
|
|
PSMA PET Imaging and Targeted Therapies: A Case Study on High-Risk Localized Prostate Cancer
|
|
Tian Zhang, MD, MHS
|
| in this series, State-of-the-Art Interdisciplinary Management of Prostate Cancer, Tian Zhang discusses a case of high-risk localized prostate cancer as part of an Independent Medical Education Initiative.
|
|
|
|
|
|
|
|
|
|
|
|
| Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer |
Alicia Morgans, MD, MPH
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase-three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
Integrating Telehealth into Urology, AUA's 2023 Quality Improvement Summit
|
Kara Watts, MD, and Jennifer Robles, MD, MPH
Kara Watts and Jen Robles share insights from the AUA's 2023 Quality Improvement Summit, which focused on integrating telehealth into urology. They discussed the importance of telehealth in providing safe, effective, and satisfactory care, especially for patients with sensitive needs or disabilities.
|
|
|
|
|
|
|
|
|
|
|
| Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings |
Andrea Apolo, MD
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. |
|
|
|
|
|
|
|
|
|
|
| Biological Pathways in Urothelial Carcinoma |
| Carissa Chu, MD |
| Carissa Chu joins Sam Chang to discuss data on genetic changes and alterations in urothelial carcinoma. The purpose of the study is to characterize human epidermal growth factor receptor 2 (HER2) (ERBB2) and fibroblast growth factor receptor 3 (FGFR3) mutations in a prospectively collected cohort of urothelial cancers. |
|
|
|
|
|
|
|
|
|
|
|
| Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study |
Shilpa Gupta, MD
Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. |
|
|
|
|
|
|
|
|
|
|
|
PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer
|
|
Louise Emmett, MD, MBChB, FRACP, FAANMS
|
| In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
| Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer |
Rana R. McKay, MD
Rana McKay joins Alicia Morgans to discuss CDK4/6 inhibitors as part of this Independent Medical Education Initiative, Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC.
|
|
|
|
|
|
|
|
|
|
|
|
Promising New Bladder Cancer Data Presented at 2023 SUO Meeting
|
|
Laura Bukavina, MD
|
| Ashish Kamat and Laura Bukavina discuss key findings from the SUO 2023 meeting, focusing on bladder cancer research. Dr. Bukavina highlights promising results from the BOND-003 study on cretostimogene, showing a 75.7% complete response rate, and the ENVISION trial on UGN-102, which demonstrated a 79.2% complete response for recurrent low-grade bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Prostate Cancer Foundation's Guidelines for Black Men in the US |
Isla Garraway, MD, Ph.D.
Sam Washington and Isla Garraway discuss the Prostate Cancer Foundation's new screening guidelines for prostate cancer in Black men. Dr. Garraway highlights the guidelines' development process, involving a diverse panel from various disciplines, including patient advocates, to address the unique risks Black men face regarding prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
Innovation in Oncology Drug Pricing: A Comparative Study of Savings Potential
|
|
Ruchika Talwar, MD
|
| Ashish Kamat hosts Ruchika Talwar and Brian Cortese to discuss a study comparing costs of generic oncology drugs bought via Mark Cuban Cost Plus Drug Company and Medicare.
|
|
|
|
|
|
|
|
|
|
|
|
| Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer |
María Bourlon, MD, MSc
Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. |
|
|
|
|
|
|
|
|
|
|
|
LuTectomy Study Shows Promise: Targeted Radiation Safe Before Prostate Cancer Surgery
|
|
Renu Eapen, MBBS, FRACS (Urol), and Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD
|
| Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery
|
|
|
|
|
|
|
|
|
|
|
|
|
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cance
|
Amanda Nizam, MD
Amanda Nizam presents findings from the UNITE study exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab.
|
|
|
|
|
|
|
|
|
|
|
|
Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer
|
|
Elisabeth I. Heath, MD, FACP
|
| Elisabeth Heath discusses germline and somatic testing literacy as part of this online medical education program entitled Beyond Androgen Blockade, to New Pathways and Novel Treatments in MHSPC and MCRPC.
|
|
|
|
|
|
|
|
|
|
|
|
| INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence |
Neha Vapiwala, MD, FACR, FASTRO
Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI-designated cooperative groups. |
|
|
|
|
|
|
|
|
|
|
|
Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options?
|
|
Brenda Martone, MSN, ANP-BC, AOCNP
|
| Brenda Martone joins Alicia Morgans in this presentation and discussion on the topic of treatment decision-making in metastatic hormone-sensitive prostate cancer, the medical oncologist and patient, what the patient needs to know about his disease, and treatment options.
|
|
|
|
|
|
|
|
|
|
|
|
| Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials |
Cheryl Lee, M
Alicia Morgans and Cheryl Lee discuss the need for equitable representation in clinical trials. Dr. Lee emphasizes the underrepresentation of minorities, low-income individuals, and those in rural areas. |
|
|
|
|
|
|
|
|
|
|
|
|
The Evolution of PSMA Theranostics: A 30-Year Journey with the Prostate Cancer Foundation
|
|
Andrea Miyahira, Ph.D.
|
| Zach Klaassen speaks with Andrea Miyahira about the Prostate Cancer Foundation’s (PCF) significant contributions to the development of PSMA theranostics in prostate cancer. Celebrating its 30th anniversary, PCF has invested over $30 million in PSMA-related research, leading to FDA-approved imaging agents and therapies like Pluvicto.
|
|
|
|
|
|
|
|
|
|
|
|
| The EV-302 Study and the Implications for Metastatic Bladder Cancer Care |
Cora N. Sternberg, MD
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. |
|
|
|
|
|
|
|
|
|
|
| Decoding the Complex Interplay of Hormone Therapy and Lineage Plasticity in Prostate Cancer |
| Amina Zoubeidi, MSc, Ph.D. |
| Amina Zoubeidi delves into her research on prostate cancer lineage plasticity. She highlights her team’s paper, "ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer," published in Cell Reports. |
|
|
|
|
|
|
|
|
|
|
|
| Association of Plant-Based Diet Index with Quality of Life in Patients with Prostate Cancer |
Stacy Loeb, MD
Stacy Loeb shares her significant research on the impact of plant-based diets on prostate cancer risk. The conversation pivots around Dr. Loeb's study which builds on earlier findings that higher plant-based food consumption correlates with lower fatal prostate cancer risk. |
|
|
|
|
|
|
|
|
|
|
|
The Impact of Screening Practices for Black Men
|
|
Leanne Woods-Burnham, MD
|
| Samuel Washington engages with Leanne Woods-Burnham to delve into prostate cancer screening for Black men in the U.S., highlighting their discussion at the SUO conference. Dr. Woods-Burnham emphasizes the decline in localized prostate cancer detection following 2012 guideline changes and a concerning rise in metastatic diagnoses, disproportionately affecting Black men.
|
|
|
|
|
|
|
|
|
|
 |
 |
